Get Integrated Data for Your Specialty and Interest Aresa
Category Select :
Items 61 ~ 80 of 26060, Page 4 of 1303
61. Research to Prevent Blindness and American Academy of Ophthalmology Award Grants for Big Data Research to Improve Patient Care - 07/30/2019
 American Academy of Ophthalmology
  Award recipients to use IRIS Registry database to learn more about cataract surgery, retinal diseases, and pink eye
62. Study: Hormone Treatment for Prostate Cancer Linked With Dementia - 07/30/2019
 American Cancer Society
  Researchers from the University of Pennsylvania found that older prostate cancer patients getting hormone treatment, called androgen deprivation therapy (ADT), were more likely to be diagnosed later with Alzheimer’s disease or dementia.
63. Smoking Impedes Embolization Treatment in Lungs - 07/30/2019
 Radiological Society of North America
  Smoking reduced the chance of a successful procedure to treat blood vessel abnormalities in the lungs. / Researchers looked at 103 patients who underwent embolization for pulmonary arteriovenous malformations. / Smokers had a five-year PAVM persistence rate of 26.3 percent compared with 13.5 percent in nonsmokers.
64. Merck Announces Second-Quarter 2019 Financial Results - 07/30/2019
65. Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP) - 07/29/2019
66. European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma - 07/29/2019
  Opinion Granted Based on Significant Overall Survival Benefit for KEYTRUDA in Combination with Axitinib Compared to Sunitinib in Phase 3 KEYNOTE-426 Trial
67. Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC) - 07/29/2019
  KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Statistically Significant Improvement in pCR Rates as Neoadjuvant Therapy for TNBC Regardless of PD-L1 Status / Data to be Presented at an Upcoming Medical Congress and Discussed with Regulatory Authorities
68. WHO launches new report on the global tobacco epidemic - 07/26/2019
  Progress being made in fight against tobacco, but increased action needed to help people quit deadly products
69. How much water should I drink? - 07/26/2019
 American Cancer Society
  You may have heard you should drink 8 glasses of water a day. The truth is close to that, but depends on details about you. Find out out how much water you really need.
70. Getting a Second Opinion - 07/25/2019
 American Cancer Society
  When you’re dealing with a serious medical issue, consulting with another doctor can be an important step to finding the best care. We’ll tell you the whys and hows of getting a second opinion.
71. Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019 - 07/24/2019
  New Findings from Study Evaluating Islatravir in Combination with Doravirine versus DELSTRIGO™ (doravirine 100 mg/3TC 300 mg/tenofovir disoproxil fumarate 300 mg) / Company Plans to Initiate Phase 3 Trials
72. WHO applauds Rwanda’s Ebola preparedness efforts - 07/24/2019
73. Study: Lack of Education About Melanoma May Contribute to Black-White Survival Disparities - 07/23/2019
 American Cancer Society
  It’s true that people with darker skin have a lower risk of melanoma. But as a recent study of non-Hispanic black Americans showed, it’s also true that they’re more likely to have lower survival rates when they are diagnosed. That’s partly because compared with non-Hispanic whites, people with darker skin are more often diagnosed with later-stage melanoma (after it’s spread). It’s also because the most common type of melanoma for them?called acral lentiginous melanoma (ALM)?has a lower survival rate.
74. Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant - 07/23/2019
  Phase 1 Data Presented Today at IAS 2019
75. Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment - 07/23/2019
  Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
76. Medtronic Requests Approval of Non-Adjunctive Labeling from FDA - 07/23/2019
  DUBLIN, July 23, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT),?the global leader in medical technology, services and solutions, today announced its Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA) requesting approval for non-adjunctive labeling for its Guardian™ Sensor 3, as part of the MiniMed™ 670G system. If the FDA approves a sensor with non-adjunctive labeling, it means that a sensor is accurate enough to be used to calculate an insulin dose for meals and to correct high glucose levels. Since Medicare requires a non-adjunctive label for sensor reimbursement, if approved, this labeling could broaden patient access by allowing for Medicare coverage of the world’s first and still the only commercially available hybrid closed loop system.
77. Merck Announces Fourth-Quarter 2019 Dividend - 07/23/2019
78. WHO recommends dolutegravir as preferred HIV treatment option in all populations - 07/22/2019
79. Medtronic Partners with to Accelerate Adoption of New Artificial Intelligence Software in U.S. Stroke Centers - 07/22/2019
  Technology Has the Potential to Save Crucial Time and Increase Access to Lifesaving Stroke Treatments
80. Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect - 07/22/2019
  New Connected Feeder Helps Pet Owners Monitor and Understand Eating Behavior of Pets
<<  <  [1]  [2]  [3]  [4[5]  [6]  [7]  [8]  [9]  [10]  >  >>

Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email :